BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19714814)

  • 1. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
    Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
    J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines.
    Di Michele M; Della Corte A; Cicchillitti L; Del Boccio P; Urbani A; Ferlini C; Scambia G; Donati MB; Rotilio D
    Biochim Biophys Acta; 2009 Feb; 1794(2):225-36. PubMed ID: 18973835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.
    Cicchillitti L; Della Corte A; Di Michele M; Donati MB; Rotilio D; Scambia G
    Int J Oncol; 2010 Aug; 37(2):445-54. PubMed ID: 20596672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers.
    Di Michele M; Marcone S; Cicchillitti L; Della Corte A; Ferlini C; Scambia G; Donati MB; Rotilio D
    J Proteomics; 2010 Mar; 73(5):879-98. PubMed ID: 19951750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
    Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
    Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
    Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
    Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.
    Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ
    J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.
    Sun QL; Sha HF; Yang XH; Bao GL; Lu J; Xie YY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):521-32. PubMed ID: 20499251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of patupilone resistance.
    Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
    Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines.
    Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
    Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
    Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
    Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.